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Evaluation of concurrent medications pre- and post initiation
of long-acting injectable antipsychotic therapy
Lindsay Pokallus, PharmD; Laurence Karper, MD; Jessica Price, PharmD, BCPS • Lehigh Valley Health Network • Allentown AND BETHLEHEM, PA

Purpose
Retrospectively evaluate concurrent psychotropic medications in
schizophrenic patients prior to- and during long-acting injectable (LAI)
antipsychotic therapy

Background
 Approximately one percent (1%) of the adult population (2.4 million) has
schizophrenia1
S
 chizophrenic patients oftentimes have multiple comorbid mental and
2
substance-abuse issues, and other health-related comorbidities
 Medication compliance is of immense importance in these patients2,3,4
– Non-adherence or partial medication compliance occurs in >50% of
5
schizophrenic patients

 Olfson et al. found that patients receiving LAI preparations compared
with oral antipsychotics continued to require multiple concurrent oral
psychotropics8
8
– Antidepressants, anxiolytics/hypnotics, mood stabilizers, and oral antipsychotics
 Shi et al. evaluated characteristics of patients taking LAI antipsychotics
versus oral antipsychotics9
– Two-thirds of LAI antipsychotic group concurrently received more psychotropic
9
medications compared to those on oral antipsychotics only
– LAI antipsychotic group tended to be more difficult-to-treat, non-compliant and
refractory to traditional oral antipsychotics9
 If LAI antipsychotics can decrease the number of concurrent
psychotropic medications, this may increase patient compliance
 No trials directly assess the number of concurrent psychotropic
medications prior to- and during LAI antipsychotic therapy

 Primary goals of therapy: minimize or eliminate the symptoms of
schizophrenia, maximize the patients’ quality of life and social functioning,
maintain a level of mental stability6

Study Design

 Meta-analysis reviewed 613 outpatient ‘mirror-image’ studies
7
– Assessed evidence of efficacy for oral versus LAI antipsychotic medications
– Hospitalization days for patients taking LAI antipsychotic medications versus
oral preparations: 17,860 versus 75,492 days7
– Relapse rates for patients using LAI antipsychotics compared to oral
7
preparations: 30% versus 47.1% patients, statistically significant

 Inclusion criteria:
– Patients prescribed LAI antipsychotic (fluphenazine decanoate, haloperidol
decanoate, paliperidone palmitate, and long-acting risperidone) for a minimum
period of 180 days for schizophrenia
– Patients who received LAI antipsychotic between January 2004 and July 2010

7

 Retrospective chart review

 The primary outcome of the study will be the number of concurrent
psychotropic medications prior to LAI antipsychotic therapy, and during
LAI antipsychotic treatment
 The secondary outcome will be patient relapse rates prior to LAI
antipsychotic therapy, and during LAI antipsychotic treatment

Lehigh Valley Hospital–Muhlenberg
2226_Lindsay Pokallus-Concurrent Medications_Rev.indd 1

Lehigh Valley Hospital–Cedar Crest

Methods
 Chart review evaluating number of concurrent psychotropic medications and
relapse rates prior to- and during LAI antipsychotic treatment
– Number of concurrent psychotropic medications will be tallied for 180 days prior toand 180 days during LAI antipsychotic treatment
– Relapse rate will be examined, as indicated by number of emergency room visits,
hospitalizations and admissions for a schizophrenic episode
– Psychotropic medications: any medication used to treat symptoms of a mental disorder,
including schizophrenia, depression, bipolar disorder, anxiety disorders, and attention
deficit-hyperactivity disorder (ADHD)
 Other patient data to be collected includes:
– Age, gender, weight, renal function
– Patient comorbidities, age and date of schizophrenia diagnosis, previously documented
failed medications
– Dates and durations of admissions for schizophrenia exacerbations
– Patient Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) information
for diagnosis, Positive and Negative Syndrome Scale (PANSS) symptoms
– Factors that may have contributed to acute episodes or mental/mood status changes
(including acute illness, trauma, illicit drug use)
 Following data collection, the number of concurrent psychotropic medications
and relapse rates will be compared
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